Drug Profile
Research programme: Wnt pathway activators - Biosplice Therapeutics
Alternative Names: Research programme: Wnt pathway activators - Wintherix; WX 04554Latest Information Update: 19 Apr 2021
Price :
$50
*
At a glance
- Originator Wintherix
- Developer Biosplice Therapeutics
- Class Small molecules
- Mechanism of Action Osteogenesis stimulants; Wnt signalling pathway stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Bone disorders
Most Recent Events
- 15 Apr 2021 Samumed is now called Biosplice Therapeutics
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-disorders in USA
- 01 Sep 2013 Winterix is now called Samumed